The GLP Peptide Family Explained

The glucagon-like peptide family belongs to the broader proglucagon-derived peptide group, which arises from tissue-specific post-translational processing of the proglucagon precursor. In enteroendocrine L-cells of the intestine, prohormone convertase 1/3 cleaves proglucagon to yield glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and several related fragments. This article summarizes the family at a laboratory-research level and does not describe therapeutic use.

GLP-1 is the most extensively studied member of the family. Its receptor, GLP-1R, is a class B G-protein-coupled receptor expressed in pancreatic islets, the central nervous system, and other tissues. In cellular assays it couples primarily to Gαs and elevates intracellular cAMP, a signaling readout that has been characterized in HEK293 and CHO cell lines stably expressing recombinant GLP-1R. Reviews on PubMed cover the receptor pharmacology in depth.

GLP-2 shares sequence homology with GLP-1 but signals through a distinct receptor, GLP-2R, with a tissue distribution centered on the gastrointestinal tract. Research literature has focused on its role in intestinal epithelial biology in preclinical models. The two peptides are typically studied with different in-vitro assay platforms even though their precursor and processing pathway overlap.

The tri-agonist class refers to synthetic peptide analogs engineered to activate more than one receptor within the incretin and glucagon family — commonly some combination of GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). These molecules are of active research interest in receptor pharmacology and structure–activity relationship studies. In-vitro characterization typically involves parallel cAMP or β-arrestin recruitment assays across each recombinant receptor to quantify relative potency.

For any of these peptides, laboratory work depends on well-characterized reference material. Sequence variants, single amino-acid substitutions, and fatty-acid conjugates behave differently in receptor-binding assays, so the identity documentation on the COA — full sequence, molecular weight, and purity — is not a formality but a prerequisite for interpretable results. Storage and reconstitution follow the general principles outlined elsewhere in these lab notes.

All materials described are for in-vitro laboratory research only and are not for human or veterinary use.